News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
419,024 Results
Type
Article (26559)
Company Profile (142)
Press Release (392323)
Section
Business (130525)
Career Advice (1276)
Deals (24009)
Drug Delivery (94)
Drug Development (59037)
Employer Resources (121)
FDA (9787)
Job Trends (9915)
News (227505)
Policy (21573)
Tag
Academia (1462)
Alliances (32360)
Alzheimer's disease (737)
Approvals (9744)
Artificial intelligence (84)
Bankruptcy (233)
Best Places to Work (7420)
Biosimilars (67)
Biotechnology (66)
Breast cancer (62)
Cancer (577)
Career advice (1058)
Cell therapy (89)
Clinical research (47860)
Collaboration (185)
Compensation (67)
COVID-19 (1545)
Data (521)
Diabetes (93)
Diagnostics (3164)
Drug pricing (88)
Earnings (52403)
Employer resources (109)
Events (57206)
Executive appointments (169)
FDA (10032)
Funding (149)
Gene therapy (87)
GLP-1 (514)
Government (2642)
Healthcare (10061)
Infectious disease (1601)
Inflammatory bowel disease (74)
Interviews (176)
IPO (10361)
Job creations (2702)
Job search strategy (951)
Layoffs (283)
Legal (5010)
Lung cancer (115)
Manufacturing (116)
Medical device (5118)
Medtech (5121)
Mergers & acquisitions (13626)
Metabolic disorders (313)
Neuroscience (894)
NextGen Class of 2024 (3451)
Non-profit (2108)
Northern California (656)
Obesity (199)
Opinion (184)
Patents (75)
People (37113)
Pharmaceutical (75)
Phase I (14557)
Phase II (20494)
Phase III (16499)
Pipeline (157)
Policy (65)
Postmarket research (1876)
Preclinical (5307)
Radiopharmaceuticals (169)
Rare diseases (128)
Real estate (3695)
Regulatory (14724)
Research institute (1319)
Resumes & cover letters (197)
Southern California (624)
Startups (2336)
United States (6430)
Vaccines (299)
Weight loss (178)
Date
Today (106)
Last 7 days (372)
Last 30 days (1730)
Last 365 days (23592)
2024 (19044)
2023 (25823)
2022 (34304)
2021 (36148)
2020 (34288)
2019 (27891)
2018 (21464)
2017 (21845)
2016 (20688)
2015 (24179)
2014 (18628)
2013 (15244)
2012 (16398)
2011 (16843)
2010 (15323)
Location
Africa (542)
Arizona (60)
Asia (29084)
Australia (3944)
California (1479)
Canada (769)
China (135)
Colorado (69)
Connecticut (56)
Europe (60699)
Florida (208)
Illinois (148)
Indiana (122)
Kansas (61)
Maryland (227)
Massachusetts (1213)
Michigan (65)
Minnesota (105)
New Jersey (568)
New York (511)
North Carolina (435)
Northern California (656)
Ohio (70)
Pennsylvania (396)
South America (788)
Southern California (624)
Texas (183)
Washington State (216)
419,024 Results for "amo pharma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Policy
AMO Pharma Completes Meeting with U.S. FDA and Outlines Plans to Advance Clinical Development of AMO-02 (tideglusib) in Treatment of Myotonic Dystrophy
AMO Pharma Limited provided an update on plans to advance the clinical development program for AMO-02, the company’s investigational therapy in development for the treatment of Type 1 myotonic dystrophy, following a recent meeting with the U.S. Food and Drug Administration.
May 2, 2024
·
5 min read
Business
AMO Pharma Announces Collaboration with Population Health Research Institute to Advance Proof of Concept Clinical Trial to Assess Efficacy of Tideglusib in Treatment of Arrhythmogenic Cardiomyopathy
AMO Pharma Limited announced a collaboration with Population Health Research Institute, a joint institute of McMaster University and Hamilton Health Sciences in Canada, to advance a clinical proof of concept trial to assess the efficacy of AMO-02, AMO Pharma’s investigational oral glycogen synthase kinase 3 beta inhibitor, in the treatment of genotype positive arrhythmogenic cardiomyopathy.
February 15, 2024
·
4 min read
Drug Development
AMO Pharma Announces Preclinical Data Showing AMO-02 Improves Muscle Function, Glucose Handling and CNS function in Mouse Models of Duchenne Muscular Dystrophy
AMO Pharma Limited (“AMO Pharma”) today announced initial preclinical data from a study of the use of the company’s investigational therapy AMO-02 in the treatment of Duchenne muscular dystrophy (DMD).
September 19, 2023
·
5 min read
AMO Pharma Announces Affirming Data from REACH-CDM Clinical Trial for AMO-02 in Treatment of Myotonic Dystrophy
AMO Pharma Limited, a privately held clinical-stage specialty biopharmaceutical company focusing on rare childhood-onset neurogenetic disorders with limited or no treatment options, announced results from the company’s REACH-CDM clinical study of the investigational therapy AMO-02 in the treatment of children and adolescents with congenital myotonic dystrophy.
September 6, 2023
·
6 min read
AMO Pharma Announces Completion of Treatment of Last Patient in Pivotal REACH-CDM Clinical Trial in Myotonic Dystrophy
AMO Pharma Limited announced completion of treatment for the final patient enrolled in the company’s REACH-CDM clinical study of the investigational therapy AMO-02.
April 25, 2023
·
4 min read
AMO Pharma Announces Completion of Enrollment in REACH-CDM Study in Congenital Myotonic Dystrophy
AMO Pharma Limited announced completion of patient enrollment in the company’s REACH-CDM study of the investigational therapy AMO-02 in treatment of congenital myotonic dystrophy.
December 6, 2022
·
2 min read
Opinion
Opinion: A Small Pharma Mindset Can Reshape Big Pharma and Improve Patient Care
An appreciation for practicality, independent thinking and patient care can help disrupt the bureaucracy of Big Pharma.
September 12, 2024
·
3 min read
·
Jill Marie Drury
Policy
AMO Pharma Announces MHRA Confirmation of CDM1-RS as Approvable Primary Outcome Measure in Myotonic Dystrophy
AMO Pharma Limited announced that the UK Medicines and Healthcare products Regulatory Agency has confirmed that the Congenital DM1 Rating Scale can be considered an approvable primary outcome measure in clinical trials to develop a treatment for congenital myotonic dystrophy type 1.
February 27, 2023
·
5 min read
Layoffs
Athira Pharma to Lay Off 70% of Workforce
Athira Pharma will cut about 49 positions, including two people in the C-suite. The announcement follows the company’s disappointing results for its investigational Alzheimer’s therapy.
September 23, 2024
·
1 min read
·
Angela Gabriel
Business
Astellas Pharma Opens Cambridge Life Sciences Center Featuring Incubator Space
Astellas Pharma’s new life sciences center houses its first U.S.-based SakuLab, an incubator space for external partners, as well as its engineered small molecules unit.
September 6, 2024
·
1 min read
·
Angela Gabriel
1 of 41,903
Next